Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome.
OBJECTIVE
To report the use of intravitreal injection of triamcinolone acetonide during the acute phase of Vogt-Koyanagi-Harada disease.


METHODS
Prospective interventional case series.


METHODS
Three eyes from two patients at the acute phase of Vogt-Koyanagi-Harada disease with serous retinal detachments were treated with a 4-mg intravitreal injection of triamcinolone acetonide. The following variables were evaluated: visual acuity, intraocular pressure, and height of the serous retinal detachment using optical coherence tomography.


RESULTS
The optical coherence tomography images showed a marked decrease in the retinal detachment in the first week after the injection with subsequent return to normal retinal thickness in all eyes.


CONCLUSIONS
Intravitreal triamcinolone acetonide provides short-term improvement in visual acuity and serous retinal detachments associated with Vogt-Koyanagi-Harada disease. These findings should be followed by future studies to evaluate long-term effects.
Andrade
Rafael E
RE
Instituto da Visão, IPEPO, Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil. rafaelernane@uol.com.br
Muccioli
Cristina
C
Farah
Michel E
ME
Nussenblatt
Robert B
RB
Belfort
Rubens
R
D000208:Acute Disease; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D008875:Middle Aged; D011446:Prospective Studies; D012163:Retinal Detachment / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014607:Uveomeningoencephalitic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D014792:Visual Acuity; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide